SORAMAX

Description

Description:

Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received “Fast Track” designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway. 

Drug type:

 Sorafenib is a targeted therapy. Sorafenib is classified as a, Tyrosine Kinase inhibitor, Angiogenesis Inhibitor, VEGF inhibitor

Indications:

• Advanced Renal Cell Carcinoma

• Gastrointestinal Stromal Tumors

• Hemangiosarcoma

• Unresectable Hepatocellular Carcinoma

• Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma
• Metastatic refractory to radioactive iodine treatment Thyroid carcinoma

Strength :